530 related articles for article (PubMed ID: 27112532)
21. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
Tak PP; Thurlings RM; Rossier C; Nestorov I; Dimic A; Mircetic V; Rischmueller M; Nasonov E; Shmidt E; Emery P; Munafo A
Arthritis Rheum; 2008 Jan; 58(1):61-72. PubMed ID: 18163485
[TBL] [Abstract][Full Text] [Related]
22. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
Lu P; Fleischmann R; Curtis C; Ignatenko S; Clarke SH; Desai M; Wong SL; Grebe KM; Black K; Zeng J; Stolzenbach J; Medema JK
Lupus; 2018 Feb; 27(2):290-302. PubMed ID: 28691866
[TBL] [Abstract][Full Text] [Related]
23. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
24. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
25. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus.
Tanaka Y; Yamamoto K; Takeuchi T; Nishimoto N; Miyasaka N; Sumida T; Shima Y; Takada K; Matsumoto I; Saito K; Koike T
Mod Rheumatol; 2007; 17(3):191-7. PubMed ID: 17564773
[TBL] [Abstract][Full Text] [Related]
26. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
[TBL] [Abstract][Full Text] [Related]
27. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
28. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
[TBL] [Abstract][Full Text] [Related]
29. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus.
Pena-Rossi C; Nasonov E; Stanislav M; Yakusevich V; Ershova O; Lomareva N; Saunders H; Hill J; Nestorov I
Lupus; 2009 May; 18(6):547-55. PubMed ID: 19395457
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients.
Zhu T; Keirns J; Howieson C; Kaibara A; Goldwater R; Kivitz AJ; Chindalore V; Cohen S; Santos V; Akinlade B; Kernstock R; Delgado-Herrera L; Blahunka PC; Karrer EE; Garg JP; Samberg N; Zeiher BG
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):408-25. PubMed ID: 27410490
[TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
32. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.
Westhovens R; Houssiau F; Joly J; Everitt DE; Zhu Y; Sisco D; Van Hartingsveldt B; Mascelli MA; Graham MA; Durez P; Bouman-Thio E
J Rheumatol; 2006 May; 33(5):847-53. PubMed ID: 16583466
[TBL] [Abstract][Full Text] [Related]
33. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
[TBL] [Abstract][Full Text] [Related]
34. Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion.
Pérez-Sánchez C; Cecchi I; Barbarroja N; Patiño-Trives AM; Luque-Tévar M; Pérez-Sánchez L; Ibáñez-Costa A; Arias de la Rosa I; Ortega R; Escudero A; Castro MC; Radin M; Roccatello D; Sciascia S; Aguirre MÁ; Collantes E; López-Pedrera C;
J Cell Mol Med; 2019 Sep; 23(9):6308-6318. PubMed ID: 31347786
[TBL] [Abstract][Full Text] [Related]
35. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
36. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
Burmester GR; Feist E; Sleeman MA; Wang B; White B; Magrini F
Ann Rheum Dis; 2011 Sep; 70(9):1542-9. PubMed ID: 21613310
[TBL] [Abstract][Full Text] [Related]
37. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
[TBL] [Abstract][Full Text] [Related]
38. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus.
Cole S; Walsh A; Yin X; Wechalekar MD; Smith MD; Proudman SM; Veale DJ; Fearon U; Pitzalis C; Humby F; Bombardieri M; Axel A; Adams H; Chiu C; Sharp M; Alvarez J; Anderson I; Madakamutil L; Nagpal S; Guo Y
Arthritis Res Ther; 2018 May; 20(1):85. PubMed ID: 29720240
[TBL] [Abstract][Full Text] [Related]
39. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
40. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]